This is a non-promotional website intended for UK healthcare professionals only. Non healthcare professionals, please visit astrazeneca.co.uk.

Resources
Useful Links
Events & Training
Contact Us

Home

More Hide

Post-ASH 2025: Highlights in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Back to Knowledge Centre

Dr Helen Marr and Dr Rosalynd Johnston discuss their highlights in CLL from ASH 2025.

Copy link

Only to be shared with relevant UK haematology healthcare professionals.

CPD^® Accreditation

To support your continued professional development the resources hosted in the Knowledge Centre have been certified for CPD^® accreditation by the CPD^® Certification Service.

Please complete the Request CPD^® Certificate form to request a CPD^® accredited certificate.

You are now leaving Haematology Horizon

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue

You are now leaving Haematology Horizon

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue

Validating...

This is a non-promotional website intended for UK healthcare professionals only. Non healthcare professionals, please visit astrazeneca.co.uk.

Haematology Horizon is an educational resource intended for UK Healthcare Professionals only

This website contains non-promotional materials for educational purposes only.

By clicking “I am a UK Healthcare Professional” you are declaring and confirming that you are a Healthcare Professional within the UK and have read and understood this disclaimer. Clicking I am NOT a UK healthcare professional will take you to www.astrazeneca.co.uk.

I am NOT a UK healthcare professional

This website has been funded and developed by AstraZeneca

Legal Notice
Privacy Policy
Cookie Policy

April 2026 | GB-75428

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

This website has been funded and developed by AstraZeneca

Legal Notice
Privacy Policy
Cookie Policy

June 2025 │ GB-67073

Post-ASH 2025: Highlights in Relapsed/Refractory Chronic Lymphocytic Leukaemia

CPD^® Accreditation

Adverse events should be reported

Loading......

Loading......

Post-ASH 2025: Highlights in Relapsed/Refractory Chronic Lymphocytic Leukaemia

CPD® Accreditation

Adverse events should be reported

Loading......

CPD^® Accreditation